摘要目的:评价人类免疫缺陷病毒(human immunodeficiency virus，HIV)感染者患新型冠状病毒肺炎(COVID-19)后的相关临床特征与死亡相关性。方法:文献检索2020年1月至8月发表的有关HIV和2019新型冠状病毒(2019 novel coronavirus, 2019-nCoV)共感染的队列研究、横断面研究和病例系列，选择年龄、合并症、CD4 +T淋巴细胞计数、HIV RNA水平、抗反转录病毒方案为评价指标，使用系统综述及荟萃分析评估与病死率的关系。采用Stata 15.0软件进行荟萃分析。 结果:共纳入24篇文献，939例HIV/2019-nCoV共感染病例。总体病死率为10.3%(97/939)，高龄及合并高血压、糖尿病、肾功能不全、慢性阻塞性肺疾病/哮喘、肿瘤与病死率增加相关(95%可信区间分别为0.005～0.050，0.042～2.294，0.390～2.754，0.513～2.848，0.348～3.743，1.943～7.101， P＝0.021、0.043、0.012、0.008、0.022、0.005)。CD4 +T淋巴细胞计数<200/μL或>500/μL、HIV RNA水平低于检测下限及抗反转录病毒药物(包括替诺福韦)与病死率无相关性(均 P>0.05)。 结论:HIV感染人群患COVID-19整体预后与普通人群相似，高龄及合并高血压、糖尿病、肾功能不全、慢性阻塞性肺疾病/哮喘、肿瘤与病死率增加相关，CD4 +T淋巴细胞计数与病死率无关，初步评估主流抗HIV药物对于COVID-19无明显保护作用。

abstractsObjective:To investigate the clinical features and their relationship with mortality of coronavirus disease 2019 (COVID-19) in people living with human immunodeficiency virus (HIV).Methods:A thorough literature review was conducted about peer-reviewed publications including cohort study, cross-sectional research, and case series on HIV/2019 novel coronavirus (2019-nCoV) coinfection from January to August 2020. Systemic review and meta-analysis were used to investigate the correlation between mortality and clinical features including age, comorbidities, CD4 + T lymphocyte count, HIV RNA level, and anti-retroviral therapy. Stata 15.0 software was used for meta-analysis. Results:Twenty-four articles were included with a total of 939 HIV/2019-nCoV coinfected patients. Overall mortality was 10.3% (97/939). Advanced age and comorbidities, including hypertension, diabetes mellitus, renal insufficiency, chronic obstructive pulmonary disease/asthma and tumor were all significantly associated with mortality (95% confidence interval 0.005-0.050, 0.042-2.294, 0.390-2.754, 0.513-2.848, 0.348-3.743 and 1.943-7.101, respectively, P=0.021, 0.043, 0.012, 0.008, 0.022 and 0.005, respectively). There were no correlations between mortality and CD4 + T lymphocyte count <200/μL or >500/μL, HIV RNA was below the lower limit of detection, or anti-retroviral drug (including tenofovir) (all P>0.05). Conclusions:The overall prognosis of COVID-19 in people living with HIV is similar to general population. Increased mortality correlates with advanced age and comorbidities including hypertension, diabetes mellitus, renal insufficiency, chronic obstructive pulmonary disease/asthma and tumor. Low CD4 + T lymphocyte count does not affect mortality. Preliminary results indicate that anti-retroviral drugs have no protective effect on COVID-19.